Effects of Sorafenib on Symptoms and Quality of Life

Ronald M. Bukowski, David Cella, Kathleen Gondek, Bernard Escudier

American Journal of Clinical Oncology · 2007 · 89 citations · 7 references

Abstract

Sorafenib shows clinical benefit without adversely impacting overall QOL and has a positive impact on some individual symptoms and concerns. These findings are consistent with other clinical results from this trial of advanced renal cell carcinoma patients treated with sorafenib, which included significantly greater progression-free survival and low risk for treatment limited toxicities.

References

7